CoChat
Sign Up
Cited by 58Inflammatory Bowel DiseaseProbiotics and Fermented FoodsGut microbiota and health

Bifidogenic growth stimulator for the treatment of active ulcerative colitis: a pilot study

Suzuki, Asuka, Mitsuyama, Keiichi, Koga, Hironori, Tomiyasu, Nobuo, Masuda, Junya, Takaki, Kosuke, Tsuruta, Osamu, Toyonaga, Atsushi +1 more·2006·Nutrition
DOI 10.1016/j.nut.2005.04.013
Open this paper in CoChat — free account

Abstract

Objectives Experimental studies have shown that luminal antigens are involved in chronic intestinal inflammatory disorders. Bifidogenic growth stimulator (BGS) is a prebiotic preparation produced by Propionibacterium freudenreichii isolated from Swiss cheese. Previously BGS was shown to act in the colon as a growth stimulator of Bifidobacteria. This study investigated the efficacy and safety of BGS in the treatment of ulcerative colitis.Methods Twelve patients with mildly to moderately active ulcerative colitis received orally 4.5 g of BGS daily for 4 wk in an open-label treatment protocol while the baseline anti-inflammatory therapy was continued. The response to treatment was evaluated clinically and endoscopically. Concentrations of short-chain fatty acids and the composition of commensal bacteria, including Bifidobacteria, Enterobacteria and Bacteroides species, were studied in stool samples.Results Patients showed improvement in their clinical activity index scores, with a significant decrease in the score from 7.4 +/- 2.8 to 4.7 +/- 1.5 (mean +/- standard error of the mean, P < 0.01). The endoscopic index score decreased from 4.4 +/- 1.7 to 2.8 +/- 1.8 (P < 0.05) with treatment. Patients showed an increase in stool butyrate concentrations after BGS treatment (P < 0.05). There were no significant changes in stool levels of bacteria as a result of BGS treatment. No side effects related to BGS were observed.Conclusions Oral BGS therapy may represent a non-toxic way to treat ulcerative colitis. However, controlled studies are needed to demonstrate its efficacy in the treatment of this disorder.

Integrity signals

Registry

Crossref · 10.1016/j.nut.2005.04.013

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Administration of a bifidogenic substance from Propionibacterium freudenreichii to patients with ulcerative colitis produced an increase in fecal butyrate associated with clinical improvement.

    “Administration of this bifidogenic substance to patients with ulcerative colitis produced an increase in fecal butyrate associated with clinical improvement.153”

    From The Gut Microbiome and the Brain (2014) · cites this paper as [153]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Suzuki, A., Mitsuyama, K., Koga, H., Tomiyasu, N., Masuda, J., Takaki, K., Tsuruta, O., Toyonaga, A., & Sata, M.
Affiliations
Kurume University (JP)
Corresponding author
Mitsuyama, Keiichi
ORCID
Venue
Nutrition
Publisher
Elsevier BV
Published
2006-01
Volume
22
Issue
1
Pages
76-81
ISSN
0899-9007 (ISSN-L)
DOI
10.1016/j.nut.2005.04.013
OpenAlex
W2105717059
Cited by
58
References
29
Citations by year
2025: 1 · 2024: 2 · 2023: 4 · 2022: 2 · 2021: 2 · 2020: 3 · 2019: 1 · 2018: 5 · 2017: 3 · 2016: 2 · 2015: 7 · 2014: 3 · 2012: 2
FWCI
1.98
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Nutrition (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Inflammatory Bowel Disease
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
Keywords
ulcerative colitis, prebiotics, Propionibacterium freudenreichii, Bifidobacterium, short-chain fatty acids, butyrate, gut microbiota, intestinal inflammation, oral therapy, treatment efficacy and safety
MeSH terms
Adolescent, Adult, Bifidobacterium, Chromatography, High Pressure Liquid, Colitis, Ulcerative, Fatty Acids, Volatile, Feces, Female, Humans, Male, Middle Aged, Pilot Projects, Propionibacterium, Safety, Severity of Illness Index, Colony Count, Microbial, Treatment Outcome, Probiotics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review